Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2011-08-16
2011-08-16
Kim, Jennifer M (Department: 1628)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C435S189000, C530S350000, C546S077000
Reexamination Certificate
active
07998970
ABSTRACT:
The present invention relates to new pharmaceutical uses of 4-azasteroid compounds, in particular of Finasteride/Dutasteride/Dutasteride and Dutasteride, particularly preferred of Finasteride/Dutasteride/Dutasteride, and its pharmaceutically acceptable derivatives, and combinations comprising said compounds. The invention also features generally the use of a modulator compound of neuroprotective conditions via beta subunits of shaker-type voltage-gated potassium channels and/or via members of solute carriers family 25, in particular Aralar (member 12) and adenine-nucleotide translocators 1 & 2 (member 4 & 5) and/or via a 4-nitrophenylphosphatase domain and non-neuronal SNAP25-like protein homolog 1 (NIPSNAP 1) as a neuroprotective medicament, particularly as a medicament for the prevention and/or treatment of neurological diseases such as dementia, Parkinson, Alzheimer, schizophrenia or epilepsy. The demonstrated inhibition of the MPTP appears to constitute a novel principle applicable to all pathological conditions which have underlying excitotoxic/mitochondrial mechanisms, like: amyotrophic lateral sclerosis, Alzheimer's disease, depression, epilepsy, multiple sclerosis, pain, Parkinson's disease, schizophrenia, traumatic brain and spinal chord injury, stroke and other ischemic conditions in the brain.
REFERENCES:
patent: 5565467 (1996-10-01), Batchelor et al.
patent: 2004/0198753 (2004-10-01), Kase et al.
patent: 0 155 096 (1985-09-01), None
patent: WO 98/38210 (1998-09-01), None
patent: WO 03/092588 (2003-11-01), None
patent: WO 2004/016595 (2004-02-01), None
Reddy, “Testosterone modulation of seizure susceptibility is mediated by neurosteroids 3alpha-androstanediol and 17beta-estradiol”, Neuroscience, vol. 129, No. 1, 2004, pp. 195-207.
Altomare et a l., “Depression circumstantially related to the administration of finasteride for androgenetic alopecia”, Journal of Dermatology, vol. 29, No. 10, Oct. 2002, pp. 665-669.
Schrattenholz Andre
Soskic Vukic
Kim Jennifer M
ProteoSys AG
Rothwell Figg Ernst & Manbeck P.C.
LandOfFree
Use of finasteride, dutasteride and related compounds for... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Use of finasteride, dutasteride and related compounds for..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Use of finasteride, dutasteride and related compounds for... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2728032